SpaceX Starship Test Flight Reaches New Heights but Ends in Setback 
FDA Pilot Program Eases Rules for Nicotine Pouch Makers 
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions 
NASA Cuts Boeing Starliner Missions as SpaceX Pulls Ahead 
Neuralink Expands Brain Implant Trials with 12 Global Patients 
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
Lost in space: MethaneSat failed just as NZ was to take over mission control – here’s what we need to know now 
CDC Vaccine Review Sparks Controversy Over Thimerosal Study Citation 
Ancient Mars may have had a carbon cycle − a new study suggests the red planet may have once been warmer, wetter and more favorable for life 
Neuren Pharmaceuticals Surges on U.S. Patent Win for Rare Disorder Drug 
Kennedy Sets September Deadline to Uncover Autism Causes Amid Controversy 
Tabletop particle accelerator could transform medicine and materials science 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
NASA Astronauts Wilmore and Williams Recover After Boeing Starliner Delay 
Several significant developments in the field of HIV/AIDS cure studies have been reported this year. Now, adding to that is an HIV vaccine entering human trials after it has been in development for more than 30 years.
HIV vaccine to be tested on over 3,000 men
The said vaccine is being developed under the efforts of pharmaceutical giant Johnson & Johnson and will undergo human testing before 2019 ends. The trials will take place in the United States and across Europe with around 3,800 male subjects who have sexual intercourse with men.
The report was confirmed by Bloomberg through the statements of the U.S. National Institute of Allergy and Infectious Diseases director Anthony Fauci. J&J and Fauci’s agency will partner with the HIV Vaccine Trials Network to push through with the testing. Parties involved reportedly expect to see results in a matter of four years or sometime in 2023.
Human trials are said to be carried out in four batches. In each session, every patient will be given six doses of the vaccine.
HIV/AIDS: Vaccine saw prior successful animal testing
The said HIV vaccine was previously tested on animals and researchers saw promising results after reportedly killing the virus for the first time on mice subjects. The procedure was successful once the scientists combined CRISPR-Cas9 or CRISPR with a type of antiretroviral treatment.
Researchers used “humanized” mice subjects infected with HIV for the animal testing of the vaccine. The treatment employs the combination of long-acting slow-effective release (LASER) ART and gene-editing tool CRISPR. In the study’s publication in Nature Communications, the researchers report seeing “viral clearance” after administering vaccines with LASER ART and CRISPR. But when used separately, the virus remained undetectable on the human-model mouse subjects.
HIV/AIDS remains a global epidemic
With the lack of cure and prevention measures that need to be improved around the world, HIV/AIDS remains a global epidemic. As of 2018, the UNAIDS reports 37.9 million people are living with HIV. Of the 37.7 million patients, over 36 million are adults, and the rest are children.
The more pressing issue from those figures is the fact that only 23.3 million people have access to ART therapy. The data also show the need to improve HIV testing drives in various regions as more than 8 million patients did not initially know of their status.
